After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Adaptimmune Therapeutics Plc ADR is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Adaptimmune Therapeutics Plc ADR is $169.17M. A total of 1.34 million shares were traded on the day, compared to an average of 1.47M shares.
In the most recent transaction, Piccina Cintia sold 24,531 shares of ADAP for 0.93 per share on Jun 18 ’24. After the transaction, the Chief Commercial Officer now owns 38,293 company shares. In a previous transaction on Jan 17 ’24, Rawcliffe Adrian sold 30,080 shares at 0.67 per share. ADAP shares that Chief Executive Officer owns now total 44,848.
Among the insiders who sold shares, Rawcliffe Adrian disposed of 9,304 shares on Jan 16 ’24 at a per-share price of $0.79. This resulted in the Chief Executive Officer holding 14,104 shares of ADAP after the transaction. In another insider transaction, Norry Elliot sold 18,276 shares at $0.67 per share on Jan 17 ’24. Company shares held by the Chief Medical Officer now total 7,785.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ADAP has a high of $2.05 and a low of $0.42.
As of this writing, ADAP has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.21. The company reported an EPS of -$0.24 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ADAP’s latest balance sheet shows that the firm has $369.58M in Cash & Short Term Investments as of fiscal 2021. There were $25.47M in debt and $62.54M in liabilities at the time. Its Book Value Per Share was $0.31, while its Total Shareholder’s Equity was $205.96M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ADAP is Buy with a score of 4.00.
